Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan-Dec;12(1):1794421.
doi: 10.1080/19420862.2020.1794421.

The Antibody Society's antibody validation webinar series

Jan L A Voskuil  1 , Anita Bandrowski  2 , C Glenn Begley  3 , Andrew R M Bradbury  4 , Andrew D Chalmers  5   6 , Aldrin V Gomes  7 , Travis Hardcastle  8 , Fridtjof Lund-Johansen  9 , Andreas Plückthun  10 , Giovanna Roncador  11 , Alejandra Solache  12 , Michael J Taussig  13 , James S Trimmer  14 , Cecilia Williams  15   16 , Simon L Goodman  17
Affiliations

The Antibody Society's antibody validation webinar series

Jan L A Voskuil et al. MAbs. 2020 Jan-Dec.

Abstract

In the wake of the reproducibility crisis and numerous discussions on how commercially available antibodies as research tool contribute to it, The Antibody Society developed a series of 10 webinars to address the issues involved. The webinars were delivered by speakers with both academic and commercial backgrounds. This report highlights the problems, and offers solutions to help the scientific community appropriately identify the right antibodies and to validate them for their research and development projects. Despite the various solutions proposed here, they must be applied on a case-by-case basis. Each antibody must be verified based on the content of the product sheet, and subsequently through experimentation to confirm integrity, specificity and selectivity. Verification needs to focus on the precise application and tissue/cell type for which the antibody will be used, and all verification data must be reported openly. The various approaches discussed here all have caveats, so a combination of solutions must be considered.

Keywords: Antibody specificity; antibody selectivity; antibody validation; monoclonal antibodies; peptide antibodies; polyclonal antibodies; recombinant antibodies; reproducibility; selective antibodies; specific antibodies.

PubMed Disclaimer

References

    1. Begley CG, Ellis LM.. Drug development: raise standards for preclinical cancer research. Nature. 2012;483(7391):531–10. PMID: 22460880. doi:10.1038/483531a. - DOI - PubMed
    1. Voskuil J. Commercial antibodies and their validation. F1000Res. 2014;3:232. PMID: 25324967. doi:10.12688/f1000research.4966.2. - DOI - PMC - PubMed
    1. Helsby MA, Fenn JR, Chalmers AD. Reporting research antibody use: how to increase experimental reproducibility. F1000Res. 2013;2:153. PMID: 24358895. doi:10.12688/f1000research.2-153.v2. - DOI - PMC - PubMed
    1. Baker M. Reproducibility crisis: blame it on the antibodies. Nature. 2015;521(7552):274–76. PMID: 25993940. doi:10.1038/521274a. - DOI - PubMed
    1. Baker M. Antibody anarchy: A call to order. Nature. 2015;527(7579):545–51. PMID: 26607547. doi:10.1038/527545a. - DOI - PubMed

Substances